Trials / Recruiting
RecruitingNCT06957431
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanzalintinib | Supplied by Exelixis, Inc. |
| DRUG | Eribulin | 1.1 mg/m\^2 dose. |
Timeline
- Start date
- 2025-10-22
- Primary completion
- 2028-11-30
- Completion
- 2033-10-31
- First posted
- 2025-05-04
- Last updated
- 2025-10-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06957431. Inclusion in this directory is not an endorsement.